Sutro Biopharma, Inc.
General ticker "STRO" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $974.8M (TTM average)
Sutro Biopharma, Inc. follows the US Stock Market performance with the rate: 9.6%.
Estimated limits based on current volatility of 6.4%: low 11.78$, high 13.38$
Factors to consider:
- Total employees count: 310 (+2.6%) as of 2024
- Top business risk factors: Early stage and no commercial products, Operational and conduct risks, Inability to maintain sales and marketing capabilities, Cybersecurity threats, Regulatory and compliance
- Price in estimated range
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [9.39$, 30.38$]
- 2025-12-31 to 2026-12-31 estimated range: [6.20$, 20.16$]
Financial Metrics affecting the STRO estimates:
- Negative: with PPE of -6.2 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -132.77 <= 0.04
- Negative: negative Industry operating cash flow (median)
- Negative: Shareholder equity ratio, % of 11.52 <= 19.35
- Negative: negative Net income
- Positive: Investing cash flow per share per price, % of 151.46 > -0.62
- Negative: Industry earnings per price (median), % of -16.21 <= 0
- Positive: Inventory ratio change, % of -41.09 <= -0.76
Short-term STRO quotes
Long-term STRO plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $67.77MM | $153.73MM | $62.04MM |
| Operating Expenses | $196.72MM | $243.01MM | $300.50MM |
| Operating Income | $-128.94MM | $-89.28MM | $-238.45MM |
| Non-Operating Income | $12.24MM | $0.68MM | $13.36MM |
| Interest Expense | $0.00MM | $12.57MM | $31.07MM |
| R&D Expense | $137.17MM | $180.43MM | $252.04MM |
| Income(Loss) | $-116.70MM | $-88.60MM | $-225.10MM |
| Taxes | $2.50MM | $18.19MM | $2.36MM |
| Profit(Loss)* | $-119.20MM | $-106.79MM | $-227.46MM |
| Stockholders Equity | $217.05MM | $149.65MM | $44.60MM |
| Assets | $406.94MM | $470.74MM | $387.21MM |
| Operating Cash Flow | $3.55MM | $-111.62MM | $-191.54MM |
| Capital expenditure | $7.86MM | $4.32MM | $3.10MM |
| Investing Cash Flow | $-35.02MM | $-3.92MM | $218.51MM |
| Financing Cash Flow | $48.31MM | $137.55MM | $94.05MM |
| Earnings Per Share** | $-23.49 | $-17.75 | $-29.61 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.